« Return to News | Drug Sponsors

AcelRx gets $20M loan

Tuesday, July 5, 2011 12:00 PM

AcelRx Pharmaceuticals has secured a $20 million loan from Hercules Technology Growth Capital, according to FierceBiotech.

Earlier this year, the developer attempted to raise $86 million in its IPO, but fell short at $40 million. AcelRx will receive $10 million to start and can draw an additional $10 million before the end of the year. The developer will make interest-only payments for a year, which could continue until September 2012 if certain development goals are met.

"This loan provides AcelRx with the resources to complete our third and last planned phase III clinical trial for ARX-01," explained CEO Richard King. ARX-01 is a drug/device combo designed to deliver the drug sufentanil to control post-operative pain. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.